Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer

Cell Death and Disease

Volumn 5, Issue 5, 2014, Pages

  Nelius, T ^a   Martinez Marin, D ^a   Hirsch, J ^a   Miller, B ^a   Rinard, K ^a   Lopez, J ^a   De Riese, W ^a   Filleur, S ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

Cyclophosphamide; Docetaxel; Low dose chemotherapy; Pigment epithelium derived factor; Prostate cancer

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CYCLOPHOSPHAMIDE; DOCETAXEL; INTERLEUKIN 8; PIGMENT EPITHELIUM DERIVED FACTOR; RETROVIRUS VECTOR; THROMBOSPONDIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL COUNT; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; LOW DRUG DOSE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SPHEROID; VIRAL GENE THERAPY;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EYE PROTEINS; GENETIC THERAPY; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NERVE GROWTH FACTORS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SERPINS; TAXOIDS; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901001344     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.180     Document Type: Article

References (60)

1. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23: 3343-3351.
2. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
4. Mukherji D, Pezaro CJ, Shamseddine A, De Bono JS. New treatment developments applied to elderly patients with advanced prostate cancer. Cancer Treat Rev 2013; 39: 578-583.
5. Filleur S, Nelius T, de Riese W, Kennedy RC. Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem 2009; 106: 769-775.
6. Becerra SP. Structure-function studies on PEDF. A noninhibitory serpin with neurotrophic activity. Adv Exp Med Biol 1997; 425: 223-237.
7. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-248.
8. Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003; 9: 774-780.
9. Halin S, Wikstrom P, Rudolfsson SH, Stattin P, Doll JA, Crawford SE et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 2004; 64: 5664-5671.
10. Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA et al. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005; 65: 5144-5152.
11. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM et al. Chemotherapyinduced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 2008; 327: 746-759.
12. Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O'Rourke D et al. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. Br J Cancer 2008; 99: 2054-2064.
13. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 2008; 7: 2649-2661.
14. Smith ND, Schulze-Hoepfner FT, Veliceasa D, Filleur S, Shareef S, Huang L et al. Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism. J Urol 2008; 179: 2427-2434.
15. Hirsch J, Johnson CL, Nelius T, Kennedy R, Riese W, Filleur S. PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFkappaB and PPARgamma. Cytokine 2011; 55: 202-210.
16. Nelius T, Samathanam C, Martinez-Marin D, Gaines N, Stevens J, Hickson J et al. Positive correlation between PEDF expression levels and macrophage density in the human prostate. Prostate 2013; 73: 549-561.
17. Halin S, Rudolfsson SH, Doll JA, Crawford SE, Wikstrom P, Bergh A. Pigment epitheliumderived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment. Neoplasia 2010; 12: 336-345.
18. Sanagi T, Yabe T, Yamada H. The regulation of pro-inflammatory gene expression induced by pigment epithelium-derived factor in rat cultured microglial cells. Neurosci Lett 2005; 380: 105-110.
19. Takanohashi A, Yabe T, Schwartz JP. Pigment epithelium-derived factor induces the production of chemokines by rat microglia. Glia 2005; 51: 266-278.
20. Yabe T, Sanagi T, Schwartz JP, Yamada H. Pigment epithelium-derived factor induces pro-inflammatory genes in neonatal astrocytes through activation of NF-kappa B and CREB. Glia 2005; 50: 223-234.
21. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006; 20: 323-325.
22. Yoshida Y, Yamagishi SI, Matsui T, Nakamura K, Imaizumi T, Yoshimura K et al. Elevated levels of pigment epithelium-derived factor (PEDF) in aqueous humor of patients with uveitis. Br J Ophthalmol 2006; 91: 149-150.
23. Eichler W, Yafai Y, Wiedemann P, Fengler D. Antineovascular agents in the treatment of eye diseases. Curr Pharm Des 2006; 12: 2645-2660.
24. Fontana A, Falcone A, Derosa L, Di Desidero T, Danesi R, Bocci G. Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients? Drugs Aging 2010; 27: 689-696.
25. Emmenegger U, Francia G, Shaked Y, Kerbel RS. Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. Recent Results Cancer Res 2010; 180: 165-183.
26. Nelius T, Rinard K, Filleur S. Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature. Cancer Treat Rev 2011; 37: 444-455.
27. Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, anddexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009; 15: 4954-4962.
28. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003; 100: 12917-12922.
29. Damber JE, Vallbo C, Albertsson P, Lennernas B, Norrby K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 2006; 58: 354-360.
30. Quesada AJ, Nelius T, Yap R, Zaichuk TA, Alfranca A, Filleur S et al. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ 2005; 12: 649-658.
31. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 2005; 11: 6678-6685.
32. Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005; 65: 7045-7051.
33. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009; 69: 4309-4318.
34. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-2868.
35. Raghavan D, Cox K, Pearson BS, Coorey GJ, Rogers J, Watt WH et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 1993; 72(Pt 1): 625-628.
36. Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide- based metronomic chemotherapy. Med Oncol 2010; 27: 363-367.
37. Koletsky AJ, Guerra ML, Kronish L. Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer. Cancer J 2003; 9: 286-292.
38. Krainer M, Tomek S, Elandt K, Horak P, Albrecht W, Eisenmenger M et al. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer. J Urol 2007; 177: 2141-2145; discussion 2145.
39. Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008; 270: 229-233.
40. Reiner T, de las Pozas A, Gomez LA, Perez-Stable C. Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis. Cancer Lett 2009; 276: 21-31.
41. Hasegawa M, Miyajima A, Kosaka T, Yasumizu Y, Tanaka N, Maeda T et al. Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer. Int J Cancer 2012; 130: 431-442.
42. Bastatas L, Martinez-Marin D, Matthews J, Hashem J, Lee YJ, Sennoune S et al. AFM nano-mechanics and calcium dynamics of prostate cancer cells with distinct metastatic potential. Biochim Biophys Acta 2012; 1820: 1111-1120.
43. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-R24.
44. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002; 62: 2731-2735.
45. Singh RK, Lokeshwar BL. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 2009; 8: 57.
46. Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res 2012; 18: 6574-6579.
47. Oudard S. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 2013; 39: 275-289.
48. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 2012; 118: 3062-3070.
49. Campbell LM, Maxwell PJ, Waugh DJ. Rationale and means to target pro-inflammatory interleukin-8 (CXCL8) signaling in cancer. Pharmaceuticals 2013; 6: 929-959.
50. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S et al. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 2011; 13: 40-48.
51. Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy. Invest New Drugs 2013; 32: 47-59.
52. Wang L, Huang X, Zheng X, Wang X, Li S, Zhang L et al. Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Clin Transl Oncol 2013; e-pub ahead of print 9 October 2013.
53. Jia L, Waxman DJ. Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett 2013; 330: 241-249.
54. Chen J, Ye L, Zhang L, Jiang WG. The molecular impact of pigment epithelium-derived factor, PEDF, on lung cancer cells and the clinical significance. Int J Oncol 2009; 35: 159-166.
55. Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther 2007; 14: 616-626.
56. Orgaz JL, Ladhani O, Hoek KS, Fernandez-Barral A, Mihic D, Aguilera O et al. 'Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma'. Oncogene 2009; 28: 4147-4161.
57. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H, Hashimoto H et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004; 64: 3533-3537.
58. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 2000; 6: 220-233.
59. Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther 2006; 5: 2435-2443.
60. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000; 6: 4950-4956.